| 高莉,方向明,唐宇凤,赵姝洁,漆晓玲,叶文春.恩格列净联合普瑞巴林治疗痛性糖尿病多发性神经病的疗效分析.[J].中南医学科学杂志.,2022,(1):75-77, 97. |
| 恩格列净联合普瑞巴林治疗痛性糖尿病多发性神经病的疗效分析 |
| Effect of enpagliflozin combined with Pregabalin in the treatment of painful diabetic polyneuropathy |
| 投稿时间：2021-04-06 修订日期：2021-05-22 |
| DOI：10.15972/j.cnki.43-1509/r.2022.01.017 |
| 中文关键词: 恩格列净 普瑞巴林 痛性糖尿病多发性神经病 疼痛评分 生存质量 |
| 英文关键词:Enpagliflozin Pregabalin painful diabetic ployneuropathy VAS quality of life |
| 基金项目:四川省卫生健康委员会科研项目(20ZD020) 作者简介:高莉,硕士,副主任医师,研究方向为糖尿病及其慢性并发症的诊断和治疗,E-mail为liligao66@126.com。通信作者叶文春,硕士,主任医师,研究方向为糖尿病及其慢性并发症的诊断和治疗,E-mail为43904635@qq.com。 |
|
| 摘要点击次数: 633 |
| 全文下载次数: 423 |
| 中文摘要: |
| 目的探索恩格列净联合普瑞巴林对痛性糖尿病多发性神经病(DPN)的疗效。 方法116例痛性DPN随机分为恩格列净联合普瑞巴林组(联合组)和普瑞巴林组,连续治疗6个月,比较两组患者治疗前、后血压、糖化血红蛋白(HbA1c)、血糖、血清肌酐及体质指数,评估患者疼痛、生存质量、焦虑情绪、神经传导速度的改善情况。 结果治疗后两组HbA1c、空腹血糖、餐后两小时血糖和血肌酐均较治疗前改善,且联合组改善较普瑞巴林组更为显著(P＜0.05)。治疗后两组VAS分、Norfolk QOL-DN评分和HAMA评分均有所改善,且联合组改善较普瑞巴林组更为显著(P＜0.05)。治疗后两组神经传导速度均有所改善,且联合组神经传导速度快于普瑞巴林组(P＜0.05)。 结论恩格列净联合普瑞巴林治疗DPN比单用普瑞巴林能够更好控制患者HbA1c、空腹血糖、餐后两小时血糖和血肌酐,改善患者疼痛、生存质量、焦虑情绪评分和神经功能。 |
| 英文摘要: |
| To explore the efficacy of Engligliflozin combined with Pregabalin on painful diabetic neuropathy. Methods116 cases of painful DPN were randomly divided into Engligliflozin combined with Pregabalin group and Pregabalin group for continuous 6 months treatment. Compare the blood pressure, glycosylated hemoglobin, blood sugar, serum creatinine and body mass index of the two groups before and after treatment. Visual analogue scale (VAS), Norfolk quality of life-diabetic neuropahey (Norfolk QOL-DN), Hamilton anxiety scale (HAMA), and nerve conduction velocity were recorded at follow-up visits. ResultsAfter treatment, HbA1c, fasting blood glucose, 2-hour postprandial blood glucose and serum creatinine were improved in both groups, and the improvement in the combined group was more significant than that in the Pregabalin group (P＜0.05). After treatment, the vas score, HQOL-DN and HAMA score were improved in both groups, and the improvement in the combination group was more significant than that in the Pregabalin group (P＜0.05). After treatment, the nerve conduction velocity was improved in both groups, and the nerve conduction velocity in the combination group was faster than that in the Pregabalin group (P＜0.05). ConclusionEnpagliflozin combined with Pregabalin in the treatment of DPN can better control HbA1c, fasting blood glucose, two-hour postprandial blood glucose and serum creatinine in patients with DPN than Pregabalin alone, and improve patients' pain, quality of life, anxiety scores and nerve function. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|